Afirma基因测序分类器与基因表达分类器的机构应用经验对比
该研究回顾性分析了272例直径>1cm的不确定甲状腺细针穿刺标本(Bethesda III和IV类),分别使用Afirma GEC或GSC检测。GSC组良性结果比例(66.7%)显著高于GEC组(45.4%,P=.002),尤其在嗜酸细胞学标本中GSC良性率80%远高于GEC的16.1%(P<.001)。GSC阳性预测值57.1%高于GEC的36.7%,但差异无统计学意义(P=.15)。
要点
- GSC检测使更多不确定甲状腺FNA标本归类为良性,良性率66.7% vs GEC 45.4%。
- 嗜酸细胞学标本中GSC良性率80%,显著高于GEC的16.1%。
- GSC阳性预测值57.1%高于GEC 36.7%,但差异无统计学意义。
核心结论
- 使用Afirma GSC相比GEC,更大比例的不确定甲状腺FNA标本被分类为良性,尤其在具有嗜酸细胞特征的样本中。
- Afirma GSC似乎具有更高的良性呼叫率。
研究设计与样本
- 回顾性研究,纳入2012年7月至2019年1月间272例直径>1cm的不确定甲状腺FNA标本(Bethesda III和IV类),使用Afirma GEC或GSC检测。
主要发现
- GEC组194个结节中88例(45.4%)Afirma结果为良性;GSC组78个样本中52例(66.7%)为良性(P=.002)。
- GEC组31例嗜酸细胞学标本中5例(16.1%)Afirma良性、26例(83.9%)可疑;GSC组10例中8例(80%)良性、2例(20%)可疑(P<.001)。
- GSC组阳性预测值57.1%,GEC组36.7%,差异无统计学意义(P=.15)。
关键数值与推荐
- GSC组良性呼叫率66.7%(52/78),GEC组45.4%(88/194),P=.002。
- 嗜酸细胞学标本中GSC良性率80%(8/10),GEC良性率16.1%(5/31),P<.001。
- GSC阳性预测值57.1%,GEC阳性预测值36.7%,P=.15。
临床怎么用
- 在不确定甲状腺FNA标本中,GSC可提高良性诊断比例,减少不必要手术,尤其对嗜酸细胞学标本。
- GSC阳性预测值仍有限,可疑结果需结合临床进一步评估。
局限性
- 回顾性单机构研究,样本量有限。
- 阳性预测值比较未达统计学显著性,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of fine-needle aspiration (FNA) to triage thyroid nodules has resulted in a significant reduction in thyroid surgery. However, approximately one-third of FNA specimens fall into the "indeterminate" category. The Afirma gene expression classifier (GEC) has been used to identify benign nodules with a high sensitivity and negative predictive value. However, the specificity and positive predictive value of the "suspicious" category are low. The updated Afirma genomic sequencing classifier (GSC) has been reported to demonstrate increased specificity while maintaining a high sensitivity and negative predictive value. METHODS: The authors retrospectively investigated 272 indeterminate thyroid FNA specimens (Bethesda categories III and IV) from nodules measuring >1 cm using the Afirma GEC or GSC tests (July 2012-January 2019). RESULTS: Of the 194 nodules tested using the Afirma GEC, a benign result was obtained in 88 cases (45.4%). In comparison, 52 of 78 FNA samples (66.7%) tested using GSC yielded a benign result (P = .002). In the GEC group, there were 31 cases with oncocytic cytology, 5 of which (16.1%) were benign on Afirma and 26 of which (83.9%) were suspicious on Afirma. In contrast, in the GSC group, there were 10 cases with oncocytic cytology, 8 of which (80%) were benign on Afirma and only 2 of which (20%) were found to be suspicious on Afirma (P < .001). The positive predictive value of the GSC group (57.1%) was higher than that of the GEC group (36.7%); however, there was no statistical significance noted (P = .15). CONCLUSIONS: A larger percentage of indeterminate thyroid FNA specimens were classified as benign using the Afirma GSC compared with the Afirma GEC, especially among samples with oncocytic features. The Afirma GSC appears to have a higher benign call rate compared with the Afirma GEC.
引用
- Wei S, Veloski C, Sharda P, et al. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. Cancer Cytopathol. 2019. PMID: 31536167. doi:10.1002/cncy.22188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。